Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified LiposarcomaRobert Hanes(Oslo University Hospital), Ola Myklebost(Oslo University Hospital)CellsFebruary 21, 201910.3390/cells8020189Cited by 20SaveCiteExport RISWatch citationsRelated PapersThe tankyrase‐specific inhibitor <scp>JW</scp>74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines|Cancer Medicine|2013|61